| http://www.w3.org/ns/prov#value | - That is the implicit problem in rare diseases: It is mostly not possible to design trials large enough to find mild drug effects,??? said lead researcher Thomas Klopstock, MD, professor of neurology at the University of Munich and coordinator of mitoNET, the German network for mitochondrial disorders. ???That is, however, why we believe in idebenone in LHON. Although the primary end point missed s
|
